Consolidative therapy for PSMA-avid lesions after 3 cycles of apalutamide plus androgen deprivation in metastatic hormone-sensitive prostate cancer: A prospective phase 2 single-arm trial
{{output}}
Background: Metastatic hormone-sensitive prostate cancer (mHSPC) with limited metastatic burden presents a therapeutic challenge, with residual PSMA-avid disease post-androgen receptor pathway inhibitor (ARPI) treatment poorly ch... ...
